Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Atossa Therapeutics Inc (ATOS)

Atossa Therapeutics Inc (ATOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Fast-food consumption by adolescent girls may sow the seeds of breast cancer decades later PR Newswire - Wed Oct 11, 2023

/PRNewswire/ -- Physician-Scientist Dr. Steven Quay, MD, PhD is calling for nutritional guidelines for adolescent girls to reduce processed and fast-food...

ATOS : 1.3700 (-3.52%)
Atossa Therapeutics and Quantum Leap Healthcare Provide Enrollment Update for (Z)-Endoxifen Arm of Ongoing I-SPY 2 Clinical Trial PR Newswire - Wed Jun 28, 2023

/PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant...

ATOS : 1.3700 (-3.52%)
Atossa Therapeutics and Quantum Leap Healthcare Announce New Study Arm to Evaluate (Z)-Endoxifen in the Ongoing I-SPY 2 Clinical Trial PR Newswire - Tue Mar 21, 2023

/PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative medicines in areas of significant...

ATOS : 1.3700 (-3.52%)
Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update Globe Newswire - Mon Aug 8, 2022

SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop...

ATOS : 1.3700 (-3.52%)
Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers Globe Newswire - Thu Jul 28, 2022

Atossa Plans to Initiate a New Development Path in Patients with Compromised Lung-Function Resulting from Cancer Treatment...

ATOS : 1.3700 (-3.52%)
Author
Atossa: Acquiring CAR-T Company Would Be a Great Move, Says Analyst TipRanks - Wed Jul 13, 2022

According to a recent 8-K filed by Atossa Therapeutics (ATOS), the biotech has signed a letter agreement with a private, venture-backed American company. One which is creating CAR-T medicines which have...

ATOS : 1.3700 (-3.52%)
Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations Globe Newswire - Thu Jun 2, 2022

SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop...

ATOS : 1.3700 (-3.52%)
Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference Globe Newswire - Wed May 18, 2022

SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop...

ATOS : 1.3700 (-3.52%)
Atossa Therapeutics to Present at the Q2 Investor Summit Conference Globe Newswire - Wed Apr 27, 2022

SEATTLE, April 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop...

ATOS : 1.3700 (-3.52%)
Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201 Globe Newswire - Wed Apr 20, 2022

NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION...

ATOS : 1.3700 (-3.52%)

Barchart Exclusives

Dividend Newcomers: Discover 3 Companies Starting To Share the Wealth Barchart - 49 minutes ago
Discover the potential of newly initiated dividends—start building your wealth with tomorrow's top dividend payers today! Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot